A new study links pathogenic cubilin gene (CUBN) variants to proteinuria without progressive renal impairment, providing reassurance for a subset of patients, calling into question the accepted pathogenesis of glomerulosclerosis and suggesting future therapeutic options.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Roscioni, S. S., Heerspink, H. J. L. & de Zeeuw, D. Microalbuminuria: target for renoprotective therapy PRO. Kidney Int. 86, 40–49 (2014).
Bedin, M. et al. Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function. J. Clin. Invest. https://doi.org/10.1172/JCI129937 (2019).
Jayasinghe, K. et al. Isolated proteinuria due to CUBN homozygous mutation – challenging the investigative paradigm. BMC Nephrol. 20, 330 (2019).
Kashtan, C. E. et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr. Nephrol. 28, 5–11 (2013).
Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).
Dickson, L. E. et al. The proximal tubule and albuminuria: really! J. Am. Soc. Nephrol. 25, 443–453 (2014).
Amsellem, S. et al. Cubilin is essential for albumin reabsorption in the renal proximal tubule. J. Am. Soc. Nephrol. 21, 1859–1867 (2010).
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).
Trachtman, H. et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J. Am. Soc. Nephrol. 29, 2745–2754 (2018).
Simons, M. The benefits of tubular proteinuria: an evolutionary perspective. J. Am. Soc. Nephrol. 29, 710–712 (2018).
Acknowledgements
The author is supported by the Royal Children’s Hospital Foundation, Melbourne Genomics Health Alliance, the KidGen Collaborative and the Australian Genomics Health Alliance. The Murdoch Children’s Research Institute is supported by the Victorian Government’s Operational Infrastructure Support Program.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Quinlan, C. CUBN variants uncouple proteinuria from kidney function. Nat Rev Nephrol 16, 135–136 (2020). https://doi.org/10.1038/s41581-019-0242-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-019-0242-4